Many muscle invasive bladder cancer patients are cured with surgery. These patents don’t need adjuvant therapy. CtDNA identifies patients at risk of relapse. ctDNA+ves also appear to benefit from adjuvant atezo. Imvigor011 (below) validates this and has screened its first patient
Amazing to see mCRPC #ProstateCancer progressing on abiraterone 👉respond to high dose testosterone (T) inj👉 huge potential when biomarkers to predict response to T available. Congrats to our faculty @neerajaiims , 3rd author on this landmark study in JCO @JCO_ASCO @NeliMUlrich